Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 23, 2008

CDC Commissions Acambis for $425M to Supply Smallpox Vaccine

  • Acambis won a $425 million, 10-year contract with the CDC to provide warm-base manufacturing capability for the ACAM2000 smallpox vaccine. If the CDC purchases more doses of the vaccine than the minimum, Acambis could make up $660 million.

    Acambis will establish a U.S.-based manufacturing capability for the vaccine, deliver against CDC orders for a minimum of 9 million doses per annum for the last eight years of the contract, and undertake activities to maintain its product licence. The CDC may purchase up to 39 million doses in the last six contract years if necessary, which would increase the value of the contract to some $660 million.

    Acambis will transfer the entire ACAM2000 production process to its facilities in Canton, MA, and Rockville, MD.
    ACAM 2000 was developed under a contract with the CDC, and over 195 million doses of the vaccine have been delivered to the CDC for the strategic national stockpile.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »